Halberd Update on WatchDawg® PTSD Treatment
Halberd (HALB) has announced the next phase of its WatchDawg® PTSD treatment study following encouraging results from an initial 10-person pilot study with veterans. The company is advancing to a larger 100-person study, to be conducted in sub-groups, with the first 10-volunteer sub-group already selected. Results from this initial sub-group are expected by mid-January. The company is currently awaiting government and private investment funding to accelerate the study's progress.
Halberd (HALB) ha annunciato la fase successiva del suo studio di trattamento per il PTSD WatchDawg®, dopo risultati incoraggianti ottenuti da uno studio pilota iniziale condotto su 10 veterani. L'azienda sta avanzando verso uno studio più ampio, che coinvolgerà 100 persone, suddiviso in sottogruppi, con il primo sottogruppo di 10 volontari già selezionato. I risultati di questo primo sottogruppo sono attesi entro la metà di gennaio. Al momento, l'azienda sta aspettando finanziamenti da enti governativi e investitori privati per accelerare il progresso dello studio.
Halberd (HALB) ha anunciado la siguiente fase de su estudio de tratamiento de PTSD WatchDawg®, tras resultados alentadores de un estudio piloto inicial con 10 veteranos. La compañía está avanzando a un estudio más grande de 100 personas, que se llevará a cabo en subgrupos, con el primer subgrupo de 10 voluntarios ya seleccionado. Se esperan resultados de este primer subgrupo para mediados de enero. La empresa está a la espera de fondos de inversión gubernamentales y privados para acelerar el progreso del estudio.
Halberd (HALB)는 초기 10명의 재향군인으로 실시된 파일럿 연구에서 긍정적인 결과에 이어 PTSD의 WatchDawg® 치료 연구의 다음 단계를 발표했습니다. 이 회사는 100명을 대상으로 하는 더 큰 연구로 나아가고 있으며, 첫 번째 10명의 자원봉사자 하위 그룹이 이미 선택되었습니다. 이 초기 하위 그룹의 결과는 1월 중순에 예상됩니다. 현재 이 회사는 연구의 진행을 가속화하기 위해 정부 및 민간 투자 자금을 기다리고 있습니다.
Halberd (HALB) a annoncé la prochaine phase de son étude de traitement du PTSD WatchDawg®, à la suite de résultats encourageants d'une étude pilote initiale avec 10 vétérans. L'entreprise passe à une étude plus large de 100 personnes, qui sera réalisée en sous-groupes, avec le premier sous-groupe de 10 volontaires déjà sélectionné. Les résultats de ce premier sous-groupe sont attendus d'ici la mi-janvier. L'entreprise attend actuellement des financements d'investissement publics et privés pour accélérer l'avancement de l'étude.
Halberd (HALB) hat die nächste Phase seiner WatchDawg®-Studie zur PTSD-Behandlung angekündigt, nachdem ermutigende Ergebnisse aus einer ersten Pilotstudie mit 10 Veteranen vorliegen. Das Unternehmen schreitet zu einer größeren Studie mit 100 Personen voran, die in Untergruppen durchgeführt wird, wobei die erste Untergruppe von 10 Freiwilligen bereits ausgewählt wurde. Die Ergebnisse dieser ersten Untergruppe werden bis Mitte Januar erwartet. Das Unternehmen wartet derzeit auf staatliche und private Investitionsmittel, um den Fortschritt der Studie zu beschleunigen.
- Progression to larger 100-person study following successful initial pilot
- First sub-group of 10 volunteers already selected for next phase
- Results expected by mid-January
- Study progression dependent on pending government and private funding
Next Phase Pilot Study
JACKSON CENTER, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.
We are awaiting government and pending private investment funding to accelerate the 100-person study currently underway.
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information, please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC PINK: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners. Halberd’s policy for responding to individual shareholder questions is to be responsive, while refraining from providing information which relates to or could compromise any information pertaining to trade secrets or that may otherwise compromise our competitive advantages. Simultaneously with such disclosure or potential disclosure, Halberd will make the responsive information public through a tweet, press release or some other form of social media/mass media communication.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2024, Halberd Corporation
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/45050da4-ae87-4679-a2f3-2e78f9ee35f2
FAQ
When will Halberd (HALB) release results from the next WatchDawg PTSD study sub-group?
How many participants will be in Halberd's (HALB) next phase PTSD treatment study?
What is the current status of Halberd's (HALB) WatchDawg PTSD treatment study?
